Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

This study has been completed.

Study NCT00006089 Information provided by National Cancer Institute (NCI)

First Received: August 3, 2000 Last Updated: March 3, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Publications:

Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, Disilvestro PA, Horowitz IR, Fiorica JV. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2009 Oct 17; [Epub ahead of print]

Fleming GF, Sill MA, Thigpen JT, et al.: Phase II evaluation of trastuzumab in patients with advanced or recurrent endometrial carcinoma: a report on GOG 181B . [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1821, 453, 2003.